Comparing the current results to its competitors, Arcus Biosciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by -39.29 %, despite the revenue increase by the most of its competitors of 22.11 %, recorded in the same quarter.
Arcus Biosciences Inc , slower than the average decrease reported by the company's competitors of -25.29 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -25.29 %
October 29, 2025
In the fast-evolving landscape of biopharmaceutical innovation, Arcus Biosciences, Inc. (NYSE:RCUS) stands at the forefront, dedicated to shaping the future of cancer treatment with its advanced therapeutic strategies and promising clinical results. The company, which operates on a global scale, focuses on developing differentiated molecules and combination therapies targeting cancer, inflammatory, and autoimmune diseases. Arcus recently unveiled its financial results for the third quarter ended September 30, 2025, alongside an update on its robust pipeline of clinical-stage investigational molecules. A momentous announcement was also made regarding new employment inducement grants, reaffirming Arcus s commi...
February 18, 2025
Arcus Biosciences Fortifies Oncology Pipeline and Financial Position with Strategic Moves Arcus Biosciences, Inc. (NYSE:RCUS), a trailblazing entity in the sphere of clinical-stage global biopharmaceutical research, recently announced transformative advancements in its pursuit of novel cancer therapies. This Hayward, California-based company has signaled commendable progress by retaining full rights to casdatifan, a potentially best-in-class HIF-2a inhibitor, and successfully securing a $150 million common stock offering. These developments underscore Arcus Biosciences unwavering commitment to spearheading next-generation oncology treatments and bolstering its financial foundation.The expiration of Gilead s...
February 17, 2025
At the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Arcus Biosciences, Inc. (NYSE: RCUS) unveiled promising new data for its lead investigational drug, casdatifan, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, indicating its potential as a best-in-class treatment option for patients with metastatic kidney cancer. The presentation was delivered by renowned researcher Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute, who highlighted the significant implications of these findings.Casdatifan operates by selectively inhibiting the HIF-2α pathway, which plays a crucial role in tumor growth and survival in cancers, particularly in renal cell carcinoma....
October 9, 2024
Harnessing Innovation in Oncology: Arcus Biosciences Poised to Unveil Pioneering ARC-20 Study Data at the 2024 EORTC-NCI-AACR Symposium HAYWARD, Calif. A beacon of innovative cancer research, Arcus Biosciences, Inc. (NYSE: RCUS), is preparing to make significant waves at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Scheduled to be held from the 23rd to the 25th of October in Barcelona, Spain, this event will witness Arcus Biosciences presenting its first-ever clinical data from the ARC-20 study, among four accepted abstracts. As a clinical-stage global biopharmaceutical company, Arcus is steadfast in its quest to discover and develop pioneering and differentiated oncolo...
October 3, 2024
Arcus Biosciences, Inc. a clinical-stage biopharmaceutical company, is gaining traction in the cancer treatment landscape through strategic collaborations and innovative therapies. This article examines significant recent developments at Arcus, including partnerships with AstraZeneca and Taiho Pharmaceutical, as well as the completion of patient enrollment for a Phase 3 trial involving domvanalimab. These initiatives underscore the company s commitment to advancing differentiated cancer therapies and the potential implications for its market position and therapeutic portfolio. As the field of oncology continues to evolve, the development of combination therapies has emerged as a potent strategy to enhance t...
May 9, 2024
Arcus Biosciences Reports Strong Financial Results and Promising Pipeline Update for Q1 2024Hayward, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer patients, announced its financial results for the first quarter ended March 31, 2024. In addition to the impressive financial figures, Arcus Biosciences provided an exciting update on its clinical-stage investigational molecules targeting various pathways, including TIGIT, the adenosine axis, HIF-2a, AXL, and PD-1, across multiple common cancers.The quarterly financial results demonstrated significant growth and success for Arcus Biosciences. The company announced a...
December 4, 2023
Exelixis and Arcus Biosciences Collaborate in Groundbreaking Trial to Combat Advanced Renal Cell Carcinoma ALAMEDA, Calif. and HAYWARD, Calif. - Biopharmaceutical giants Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) have joined forces in an exciting clinical trial collaboration for STELLAR-009. This phase 1b/2 trial aims to evaluate the potential of zanzalintinib, Exelixis cutting-edge tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2, in patients battling advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Renal cell carcinoma, a type of kidney cancer, is notoriously difficult to treat in its advanced ...
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Sources:
Arcus Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arcus Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
